Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

University of Wisconsin (UW)

Status and phase: Completed; Phase 2

Conditions: Primary Peritoneal Carcinoma; Ovarian Carcinoma

Treatments: Drug: Docetaxel; Drug: Carboplatin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00214058

2002-224 (Other Identifier)

A532820 (Other Identifier)

CO02701

SMPH/OBSTET & GYNECOL (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent ovarian or peritoneal cancer

Exclusion criteria

• No prior chemotherapy

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)